Brief: Palisade Bio Completed Murine And Non-Murine Pivotal Nonclinical Studies Using GMP PALI-2108 Drug Substance
11/07/2024 13:19
July 11 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO INC: COMPLETED MURINE AND NON-MURINE PIVOTAL
NONCLINICAL STUDIES USING GMP PALI-2108 DRUG SUBSTANCE
* PALISADE BIO: ON TRACK TO START PHASE 1 HUMAN CLINICAL
STUDY OF
PALI-2108 FOR TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
BEFORE YEAR END
Source text for Eikon: ID:nGNX4S9pNY
Further company coverage: PALI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing